AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.Tokyo, Japan, May 11, 2006 - (JCN) - AnGes MG has announced the results of its phase I clinical trials of HGF HGF, n See glucagon. (Hepatocyte Growth Factor Hepatocyte growth factor/scatter factor (HGF/SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells. ) gene medicine conducted in the US. In the trials, which covered nine serious cases, the company sought the availability of HGF gene medicine in the treatment of ischemic heart disease Ischemic heart disease Insufficient blood supply to the heart muscle (myocardium). Mentioned in: Myocarditis ischemic heart disease . The company says that no significant problem was confirmed in terms of initial safety up until three months after administration. Currently, AnGes MG is proceeding research in the fields of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. and ischemic heart disease. The company grants Daiichi Pharmaceutical rights to distribute the medicine in Japan, the US and Europe. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion